Group One Trading’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-226,200
| Closed | -$9.1M | – | 7536 |
|
|
2026
Q1 | $9.1M | Sell |
226,200
-7,700
| -3% | -$166K | 0.02% | 897 |
|
|
2025
Q4 | $5.88M | Buy |
233,900
+54,800
| +31% | +$1.29M | 0.01% | 1340 |
|
|
2025
Q3 | $4.05M | Buy |
179,100
+33,500
| +23% | +$781K | 0.01% | 1666 |
|
|
2025
Q2 | $2.52M | Sell |
145,600
-62,600
| -30% | -$1.16M | 0.01% | 1910 |
|
|
2025
Q1 | $4.55M | Sell |
208,200
-69,100
| -25% | -$1.91M | 0.01% | 1144 |
|
|
2024
Q4 | $8.85M | Sell |
277,300
-64,800
| -19% | -$1.95M | 0.02% | 779 |
|
|
2024
Q3 | $9.87M | Buy |
342,100
+62,500
| +22% | +$2.31M | 0.03% | 628 |
|
|
2024
Q2 | $10.7M | Buy |
279,600
+53,500
| +24% | +$2.42M | 0.04% | 411 |
|
|
2024
Q1 | $13.3M | Sell |
226,100
-139,600
| -38% | -$8.9M | 0.05% | 322 |
|
|
2023
Q4 | $21.9M | Sell |
365,700
-578,700
| -61% | -$29.4M | 0.06% | 310 |
|
|
2023
Q3 | $35.9M | Buy |
944,400
+885,800
| +1,512% | +$38.9M | 0.12% | 106 |
|
|
2023
Q2 | $5.34M | Sell |
58,600
-51,300
| -47% | -$4.43M | 0.02% | 913 |
|
|
2023
Q1 | $7.25M | Buy |
109,900
+8,400
| +8% | +$485K | 0.03% | 639 |
|
|
2022
Q4 | $5.25M | Buy |
101,500
+39,200
| +63% | +$2.08M | 0.01% | 1110 |
|
|
2022
Q3 | $4.25M | Buy |
62,300
+12,800
| +26% | +$757K | 0.01% | 1284 |
|
|
2022
Q2 | $2.24M | Buy |
49,500
+7,200
| +17% | +$328K | ﹤0.01% | 1959 |
|
|
2022
Q1 | $2.15M | Buy |
42,300
+22,200
| +110% | +$980K | ﹤0.01% | 2328 |
|
|
2021
Q4 | $950K | Sell |
20,100
-71,900
| -78% | -$2.83M | ﹤0.01% | 3409 |
|
|
2021
Q3 | $3.03M | Buy |
92,000
+2,900
| +3% | +$163K | ﹤0.01% | 2231 |
|
|
2021
Q2 | $5.63M | Sell |
89,100
-35,300
| -28% | -$1.82M | 0.01% | 1577 |
|
|
2021
Q1 | $5.34M | Buy |
124,400
+40,900
| +49% | +$1.94M | 0.01% | 1462 |
|
|
2020
Q4 | $4.78M | Buy |
83,500
+80,700
| +2,882% | +$3.41M | 0.01% | 1310 |
|
|
2020
Q3 | $84K | Sell |
2,800
-72,900
| -96% | -$2.18M | ﹤0.01% | 4309 |
|
|
2020
Q2 | $2.47M | Buy |
75,700
+1,600
| +2% | +$51.4K | 0.01% | 1315 |
|
|
2020
Q1 | $1.99M | Buy |
74,100
+61,200
| +474% | +$2.17M | 0.02% | 1051 |
|
|
2019
Q4 | $395K | Buy |
+12,900
| New | +$357K | ﹤0.01% | 2632 |
|
Other funds holding APLS
Group One Trading's APLS Position: Q4 2025 in Review
Group One Trading sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 14,925 shares — an estimated $350K sold.
Group One Trading first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $15.2M in Q4 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.
- Group One Trading reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 14,925 Apellis Pharmaceuticals shares in Q4 2025, an estimated $350K.
- Group One Trading first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
- Group One Trading's Apellis Pharmaceuticals position peaked at $15.2M in Q4 2023.
- 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.